1. Introduction to the text
This article discusses the success of a new topical hair loss treatment developed by an Italian pharmaceutical company, Cosmofarma, whose rights are held by the South Korean company Hyundai Pharmaceutical. The article highlights the impressive results from clinical trials and the subsequent surge in Hyundai Pharmaceutical’s stock price.
2. Vocabulary
| Korean Word | Romanization | English Meaning | Contextual Example |
|---|---|---|---|
| 탈모 | talmeo | hair loss | The new hair loss treatment showed impressive results. |
| 임상 | imsang | clinical trial | The hair loss drug underwent successful clinical trials. |
| 판권을 | panjwoneul | rights/license | Hyundai Pharmaceutical holds the rights to the hair loss drug. |
| 클라스코테론 | keullaseukoteullon | Clascoterrone (drug name) | The active ingredient in the new hair loss treatment is Clascoterrone. |
| 상한가 | sanghanga | daily price limit (upper) | Hyundai Pharmaceutical’s stock price hit the daily price limit of 29.91%. |
| 투여 | tuyeo | administration | The hair loss drug is administered by applying it to the scalp. |
| 부위 | buwi | area | The hair density increased by 539% in the treated area. |
| 모발 | mobal | hair | The new hair loss treatment significantly increased hair growth. |
| 위약 | wiayak | placebo | The hair loss drug was compared to a placebo in the clinical trials. |
| 개선 | gaeseon | improvement | The new hair loss treatment showed a 168% improvement compared to the placebo. |
3. The main text in both Korean and English
현대약품 주가가 5일 상한가로 마감했다. 이탈리아 제약사 코스모파마슈티컬스가 개발한 ‘바르는 탈모 치료제’가 임상 시험에서 성과를 거두면서, 이 제품의 국내 판권을 가진 현대약품의 주가가 상승한 것이다.
Hyundai Pharmaceutical’s stock price closed at the daily price limit on the 5th. This is because the ‘topical hair loss treatment’ developed by the Italian pharmaceutical company Cosmofarma achieved success in clinical trials, leading to a surge in the stock price of Hyundai Pharmaceutical, which holds the domestic rights to this product.
이번 임상 시험에서 클라스코테론 투여군은 위약 투여군에 비해 투여 부위 모발이 539% 늘어났다. 또 다른 임상에서도 위약 투여군 대비 168% 개선 효과를 보였다. 기존 경구 탈모약과 달리 클라스코테론은 두피에 바르는 국소 제제다.
In this clinical trial, the Clascoterrone treatment group showed a 539% increase in hair density in the treated area compared to the placebo group. Another trial also showed a 168% improvement compared to the placebo group. Unlike existing oral hair loss drugs, Clascoterrone is a topical formulation that is applied directly to the scalp.
현대약품은 이탈리아 제약사 코스모파마슈티컬스가 개발한 이 탈모 치료제의 국내 판권을 보유하고 있다. 이번 임상 시험 결과가 긍정적이었기 때문에, 현대약품 주가가 상한가까지 치솟은 것으로 보인다.
Hyundai Pharmaceutical holds the domestic rights to this hair loss treatment developed by the Italian pharmaceutical company Cosmofarma. Since the results of the clinical trials were positive, Hyundai Pharmaceutical’s stock price soared to the daily price limit.
코스모파마슈티컬스는 이번 임상 시험에서 탈모 환자 1465명을 대상으로 실험을 진행했다. 그 결과 클라스코테론 투여군이 위약 투여군에 비해 탈모 개선 효과가 월등했다는 것이 확인되었다.
Cosmofarma conducted the clinical trial on 1,465 hair loss patients. The results showed that the Clascoterrone treatment group had significantly better hair loss improvement compared to the placebo group.
현대약품은 이탈리아 제약사가 개발한 이 탈모 치료제의 국내 판권을 확보하고 있다. 이번 임상 시험 결과가 긍정적이었기 때문에, 현대약품의 주가는 상한가까지 치솟았다.
Hyundai Pharmaceutical holds the domestic rights to this hair loss treatment developed by the Italian pharmaceutical company. Since the clinical trial results were positive, Hyundai Pharmaceutical’s stock price surged to the daily price limit.
이탈리아 제약사 코스모파마슈티컬스가 개발한 이 탈모 치료제는 기존 경구 약물과 달리 두피에 바르는 국소 제제다. 이번 임상 시험에서 투여 부위 모발이 크게 늘어났다는 점이 주목을 받고 있다.
The hair loss treatment developed by the Italian pharmaceutical company Cosmofarma is a topical formulation, unlike the existing oral medications. The significant increase in hair density in the treated area during the clinical trial has drawn attention.
4. Reading comprehension questions
- What is the name of the new hair loss treatment being developed?
- What company holds the rights to this hair loss treatment in South Korea?
- How much did the hair density increase in the treated area compared to the placebo group?
- How does the new hair loss treatment differ from existing oral medications?
- Why did Hyundai Pharmaceutical’s stock price surge to the daily price limit?
5. Cultural and historical notes
The development of this new topical hair loss treatment is a significant milestone in the field of dermatology and cosmetic medicine in South Korea. The success of the clinical trials and the subsequent surge in Hyundai Pharmaceutical’s stock price reflect the growing demand and interest in effective hair loss solutions among the Korean public.